Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Neothetics (NEOT) Stock Price

Headlines about Neothetics (NASDAQ:NEOT) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neothetics earned a news impact score of 0.11 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.293329665109 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Separately, ValuEngine upgraded shares of Neothetics from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 17th.

Shares of Neothetics (NASDAQ:NEOT) remained flat at $$2.08 on Friday. The company’s stock had a trading volume of 431,400 shares, compared to its average volume of 415,433. Neothetics has a 52-week low of $0.30 and a 52-week high of $2.63. The stock has a market cap of $28.81, a P/E ratio of -3.01 and a beta of 3.33.

Neothetics (NASDAQ:NEOT) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-neothetics-neot-stock-price.html.

Neothetics Company Profile

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Insider Buying and Selling by Quarter for Neothetics (NASDAQ:NEOT)

Receive News & Ratings for Neothetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply